Limited drug sources pose risks to patient safety
The spread of COVID-19 has been a wake-up call to the world about dangers posed by over-reliance on single-country sources in the global medicine supply chain.
Antimicrobial resistance (AMR) is a global health challenge which can undermine standard treatments and procedures on which we have come to rely.
For nearly 200 years, USP’s public standards have served to establish a common foundation upon which the quality of medicines can be evaluated, building trust in the healthcare system and enabling innovation to thrive. During that time, medicine has evolved tremendously.
I was pleased to address the American Association of Pharmaceutical Scientists (AAPS) on May 12 during a webinar focused on the impact of the COVID-19 pandemic on the supply of quality medicines.
As the impact of the COVID-19 pandemic continues to unfold, each day brings to light new realizations of just how interconnected, and sometimes vulnerable, the global supply chain for medicines is.
Innovations in biotherapeutic medicines are advancing at an unprecedented pace and offer great promise for improving outcomes for patients.
As we approach our 200th anniversary year in 2020, I am proud to announce a major milestone in USP’s publication history, the conclusion of the USP–NF printed product.
With significant innovations in pharmaceuticals, including biologic drugs and treatments for rare diseases, the need for new and better functioning excipients to improve drug delivery is growing.
What happens when patients who receive a trusted treatment start experiencing adverse reactions? And what can be done to help prevent it from reoccurring?